Study on the Utilization of Cabozantinib in Adult Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC) in 2nd Line Treatment Following Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Therapy Under Real-real Life Clinical Setting in France.
Clinical trial NCT04609800 · WITHDRAWN
Trial details
- NCT number
- NCT04609800
- Sponsor
- Ipsen
- Status
- WITHDRAWN
- Study type
- OBSERVATIONAL
- Start date
- 2020-11-06
- Primary completion
- 2023-05-10
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.